Show simple item record

dc.contributor.authorChristie, DAen_US
dc.contributor.authorTansey, EMen_US
dc.contributor.editorCHRISTIE, DAen_US
dc.contributor.editorTANSEY, EMen_US
dc.date.accessioned2012-10-09T10:55:36Z
dc.date.issued2003en_US
dc.identifier.isbn0854840877en_US
dc.identifier.isbn9780854840878en_US
dc.identifier.urihttp://qmro.qmul.ac.uk/xmlui/handle/123456789/2766
dc.descriptionThe transcript of a Witness Seminar held at the Wellcome Trust Centre for the History of Medicine at UCL, London, on 15 May 2001.First published by the Wellcome Trust Centre for the History of Medicine at UCL, 2003.©The Trustee of the Wellcome Trust, London, 2003. All volumes are freely available online at: www.history.qmul.ac.uk/research/modbiomed/wellcome_witnesses/en_US
dc.descriptionAnnotated and edited transcript of a Witness Seminar held on 15 May 2001. Introduction by Professor Sir David Weatherall, Institute of Molecular Medicine, Oxford.
dc.descriptionAnnotated and edited transcript of a Witness Seminar held on 15 May 2001. Introduction by Professor Sir David Weatherall, Institute of Molecular Medicine, Oxford.
dc.descriptionAnnotated and edited transcript of a Witness Seminar held on 15 May 2001. Introduction by Professor Sir David Weatherall, Institute of Molecular Medicine, Oxford.
dc.descriptionAnnotated and edited transcript of a Witness Seminar held on 15 May 2001. Introduction by Professor Sir David Weatherall, Institute of Molecular Medicine, Oxford.en_US
dc.description.abstractThis transcript examines some of the major discoveries and developments in the management of leukaemia over the past 30 years, such as the discovery of the alkylating agents (chlorambucil and busulphan) at London’s Chester Beatty Research Institute, exchange transfusion and the exciting development of combined chemotherapy (daunorubicin and cytosine arabinoside) that led to more than 60 per cent of adults with acute myelogenous leukaemia achieving complete remission. The introduction of clinical trials and issues related to funding were also discussed. Those who contributed included Professor Daniel Catovsky, Professor David Galton, Professor John Goldman (Chair), Professor Frank Hayhoe, Professor Victor Hoffbrand, Professor Humphrey Kay, Professor John Lilleyman, Professor Ian MacLennan, Dr Gordon Piller, Dr Rosemary Shannon, and Dr Eve Wiltshaw. Christie D A, Tansey E M. (eds) (2003) Leukaemia, Wellcome Witnesses to Twentieth Century Medicine, vol. 15. London: The Wellcome Trust Centre for the History of Medicine at UCL.en_US
dc.description.sponsorshipThe Wellcome Trust Centre for the History of Medicine at UCL is funded by the Wellcome Trust, which is a registered charity, no. 210183.en_US
dc.format.extenti - 85 (95)en_US
dc.format.mediumpaper and open access
dc.format.mediumpaper and open access
dc.format.mediumpaper and open access
dc.format.mediumpaper and open accessen_US
dc.language.isoenen_US
dc.publisherWellcome Trust Centre for the History of Medicine at UCLen_US
dc.relation.ispartofWellcome Witnesses to Twentieth Century Medicineen_US
dc.subjectanti-folate drugsen_US
dc.subject6-mercaptopurineen_US
dc.subjectChester Beatty Research Instituteen_US
dc.subjectchlorambucil, melphalan and busulphanen_US
dc.subjecttrial of radiotherapy versus busulphanen_US
dc.subjectLeukaemia Unit, Hammersmith Hospitalen_US
dc.subjecthaematologyen_US
dc.subjectethicsen_US
dc.subjectabnormal chromosome patternen_US
dc.subjectclassificationen_US
dc.subjectmorphology of acute leukaemiaen_US
dc.subjectbone marrow transplantationen_US
dc.titleLeukemiaen_US
dc.typeBook
pubs.notesNot knownen_US
pubs.place-of-publicationLONDONen_US
pubs.publication-statusPublisheden_US
pubs.volume15en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record